Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: Residual volume and exhaled nitric oxide as outcome measures

Allergy and Asthma Proceedings

Volumn 28, Issue 6, 2007, Pages 691-694

  Verini, Marcello ^a   Peroni, Diego G ^b   Piacentini, Giorgio L ^b   Nicodemo, Angiolina ^a   Rossi, Nadia ^a   Bodini, Alessandro ^b   Chiarelli, Francesco ^a   Boner, Attilio L ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Anti inflammatory; Asthma control; Combination therapy; Exhaled nitric oxide; Inhaled corticosteroid; Leukotriene receptor antagonist; Long acting beta agonist; Montelukast; Pediatric; Salmeterol

Indexed keywords

ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; FLUTICASONE; MONTELUKAST; NITRIC OXIDE; QUINOLINE DERIVATIVE; SALBUTAMOL; SALMETEROL;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG COMBINATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION TEST; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPIROMETRY;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; HUMANS; NITRIC OXIDE; QUINOLINES; RESPIRATORY FUNCTION TESTS; SINGLE-BLIND METHOD; SPIROMETRY;

EID: 38349191164     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.3054     Document Type: Article

References (25)

1. National Asthma Education and Prevention Program. Expert panel report 2: Guidelines for the diagnosis and management of asthma. NHI Publication 97-4041. National Heart, Lung, and Blood Institute, Bethesda, MD, 1997.
2. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med 332:868-875, 1995.
3. Kharitonov SA, Yates DH, and Barnes PJ. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients. Am J Respir Crit Care Med 153:454-457, 1996.
4. Global Initiative for Asthma. Available online at www.ginasthma.com; last accessed Feb. 20, 2007.
5. Peroni DG, Piacentini GL, Costella S, et al. Mite avoidance can reduce air trapping and airway inflammation in allergic asthmatic children. Clin Exp Allergy 32:850-855, 2002.
6. Pool JB, Greenough A, Gleeson JGA, and Price JF. Persistent lung hyperinflation in apparently asymptomatic asthmatic children. Respir Med 83:433-436, 1989.
7. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Grit Care Med 152:1107-1136, 1995.
8. American Thoracic Society. Lung function testing: Selection of reference values and interpretative strategies. Am Rev Respir Dis 144:1202-1218, 1991.
9. Baraldi E, and De Jongste J. European Respiratory Society/ American Thoracic Society. Measurement of exhaled nitric oxide in children. 2001. Eur Repir J 20:223-237, 2002.
10. Zapletal A, Paul T, and Samanek M. Pulmonary elasticity in children and adolescents. J Appl Physiol 40:953-961, 1976.
11. Stanescu D. Small airways obstruction syndrome. Chest 116: 231, 1999.
12. Ringdal N. Long-acting beta2-agonists or leukotriene receptor antagonists as add-on therapy to inhaled corticosteroids for the treatment of persistent asthma. Drugs 63(suppl 2):21-33, 2003.
13. Stempel DA, O'Donnell JC, and Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs. J Allergy Clin Immunol 109:433-439, 2002.
14. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120:423-430, 2001.
15. Nelson HS, Busse WW, Kerwin E, et al. Fluticasone propionate/ salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106:1088-1095, 2000.
16. Buchvald F, and Bisgaard H. Comparisons of the complementary effect on exhaled nitric oxide of salmeterol vs montelukast in asthmatic children taking regular inhaled budesonide. Ann Allergy Asthma Immunol 91:309-313, 2003.
17. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared to salmeterol and fluticasone in protecting against asthma exacerbation in adults: One year, double blind, randomized, comparative trial. Br Med J 327:891-897, 2003.
18. Tsuchida T, Matsuse H, Machida I, et al. Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. Allergy Asthma Proc 26:287-291, 2005.
19. Bisgaard H, Loland L, and Anhaaj J. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast. Am J Respir Crit Care Med 160:1227-1231, 1999.
20. Ghiro L, Zanconato S, Rampon O, et al. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur Respir J 20:630-634, 2002.
21. Cai Y, Carty K, Henry RL, et al. Persistence of sputum eosinophilia in children with controlled asthma when compared with healthy children. Eur Respir J 11:848-853, 1998.
22. Liu AH. Biomarkers and childhood asthma: Improving control today and tomorrow. Allergy Asthma Proc 26:249-254, 2005.
23. Peroni DG, Piacentini GL, Bodini A, et al. Montelukast versus formoterol as second-line therapy in asthmatic children exposed to relevant allergens. Allergy Asthma Proc 26:283-286, 2005.
24. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14- year-old children: A randomized double-blind trial. Pediatric Montelukast Study Group. J Am Med Assoc 279:1181-1186, 1998.
25. Bousquet J. The relative importance of small airways in asthma. Respir Med 94:S1-S2, 2000.